Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TVTX | US
1.36
9.81%
Healthcare
Biotechnology
30/06/2024
04/10/2024
15.23
13.87
15.46
13.82
Travere Therapeutics Inc. a biopharmaceutical company focuses on the identification development commercialization and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058 a novel investigational human enzyme replacement candidate which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations CDG Care and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin Inc. and changed its name to Travere Therapeutics Inc. in November 2020. Travere Therapeutics Inc. was incorporated in 2008 and is headquartered in San Diego California.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
High Short-term Volatility
Smallcap (300M - 2B USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
70.5%1 month
87.2%3 months
67.9%6 months
63.5%-
-
70.75
26.62
0.73
-5.67
6.47
-
-275.06M
1.16B
1.16B
-
-123.90
-
68.10
-582.61
5.94
12.73
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.06
Range1M
6.12
Range3M
7.74
Rel. volume
1.23
Price X volume
48.41M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 13.09 | 1.26B | 0.23% | n/a | 53.59% |
Mesoblast Limited | MESO | Biotechnology | 10.81 | 1.26B | 23.40% | n/a | 24.76% |
Wave Life Sciences Ltd | WVE | Biotechnology | 8.41 | 1.24B | -4.76% | n/a | 656.70% |
Innoviva Inc | INVA | Biotechnology | 19.67 | 1.23B | 0.56% | 10.92 | 67.72% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 57.83 | 1.22B | 0.57% | 49.40 | 68.04% |
Fluent Inc | COGT | Biotechnology | 11.11 | 1.22B | 3.64% | n/a | 4.87% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 17.25 | 1.20B | 2.92% | n/a | -216.56% |
ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 10.02 | 1.17B | -2.05% | n/a | 111.34% |
Tyra Biosciences Inc. Common Stock | TYRA | Biotechnology | 22.04 | 1.16B | -1.52% | n/a | 1.70% |
Praxis Precision Medicines Inc | PRAX | Biotechnology | 64.94 | 1.15B | 6.22% | n/a | 0.46% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -5.67 | 0.76 | Cheaper |
Ent. to Revenue | 6.47 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 70.75 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 67.90 | 74.67 | Par |
Debt to Equity | 26.62 | -1.82 | Expensive |
Debt to Assets | 0.73 | 0.26 | Expensive |
Market Cap | 1.16B | 3.73B | Emerging |